Document issued on: May 17, 2013
The draft of this guidance document was issued on December 28, 2011.
This document supersedes “Medical Device Appeals and Complaints: Guidance for Dispute Resolution,” February 1998 and “Resolving Scientific Disputes Concerning the the Regulation of Medical Devices, A Guide to Use of the Medical Devices Dispute Resolution Panel; Final Guidance for Industry and FDA,” July 2001.
For questions regarding this document, contact the CDRH Ombudsman's office at 301-796-5699 or by electronic mail at CDRHOmbudsman@fda.hhs.gov.
See additional PRA statement in Section 7 of the guidance.
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of the Center Director
You may submit written comments and suggestions at any time for Agency consideration to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register. Comments may not be acted upon by the Agency until the document is next revised or updated.
Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 1742 to identify the guidance you are requesting.
Table of Contents
- Request for Supervisory Review under 21 CFR 10.75
- 2.1 General Considerations
- 2.1.1 Supervisory Review Hierarchy
- 2.1.2 Telescoped Review
- 2.1.3 New Information
- 2.1.4 Parallel Review
- 2.1.5 Bias and Retaliation
- 2.1 General Considerations
- The Medical Devices Dispute Resolution Panel
- 4.1 Petitions under Section 515 of the FD&C Act
- 4.2 Citizen Petition (21 CFR 10.30)
- 4.3 Petition for Administrative Reconsideration of Action (21 CFR 10.33)
- 4.4 Petition for Administrative Stay of Action (21 CFR 10.35)
- 4.5 Request for Reconsideration of Adverse Decisions on Mammography Facility Accreditation/Certification (21 CFR Part 900, Subpart B)
- 5.1 Formal Evidentiary Public Hearing (21 CFR Part 12)
- 5.2 Public Hearing Before A Board of Inquiry (21 CFR Part 13)
- 5.3 Public Hearing Before A Public Advisory Committee (21 CFR Part 14)
- 5.4 Public Hearing Before the FDA Commissioner (21 CFR Part 15)
- 5.5 Regulatory Hearing Before the Food and Drug Administration (21 CFR Part 16)
- Judicial Review
- Paperwork Reduction Act of 1995
Center for Devices and Radiological Health Appeals Processes - Guidance for Industry and Food and Drug Administration Staff
This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.
This guidance document describes the processes available to outside stakeholders to request additional review of decisions or actions by Center for Devices and Radiological Health (CDRH or the Center) employees. This guidance supersedes “Medical Device Appeals and Complaints: Guidance for Dispute Resolution,” dated February 1998 and “Resolving Scientific Disputes Concerning The Regulation of Medical Devices, A Guide to Use of the Medical Devices Dispute Resolution Panel; Final Guidance for Industry and FDA,” dated July 2001.
Individuals outside of the Food and Drug Administration (FDA) who disagree with a decision or action taken by CDRH and wish to have it reviewed or reconsidered have several processes for resolution from which to choose, including: requests for supervisory review of an action; petitions; and hearings. These processes are broadly described in FDA regulations. This document provides general information about each process, as well as guidance on how to submit related requests to CDRH and FDA.
Keep in mind as you read over this material that for any situation, multiple processes for resolution may be available. It is up to the party seeking review of an adverse decision or resolution of a difference of opinion to determine the appropriate process for a given circumstance or issue.
The most effective means of resolving a dispute between the Center and an external stakeholder is through discussion and agreement. The Center Ombudsman is available to assist in clarifying issues, mediating meetings and teleconferences, and conducting discussions with the parties in an effort to resolve disagreements short of a formal review or appeal. Before contacting the Ombudsman, a stakeholder should have made reasonable efforts to discuss the decision or action in dispute with the individual charged with managing the matter at issue, for example: the Lead Reviewer in the Office of Compliance for a Warning Letter; the Lead Reviewer in the Office of Device Evaluation or the Office of In-Vitro Diagnostics for pre-market review actions; or the Epidemiologist in the Office of Surveillance and Biometrics for a post-approval study issue. If this is unsatisfactory, it may be necessary or helpful for the relevant Branch Chief and members of Division management to be brought into the discussion. The general expectation is that the stakeholder will follow an orderly progression of interaction with Center employees followed by outreach to relevant members of Management and then engagement with the CDRH Ombudsman, prior to filing a formal request for review or appeal. However, a stakeholder may file a petition or request for review at any time that is permissible under applicable statutory and regulatory provisions.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
2. Request for Supervisory Review under 21 CFR 10.75
As mentioned earlier, the most effective means for resolving disputes is through discussion and mediation. If these approaches fail to resolve the disagreement, or if an adverse regulatory action is taken, there are several mechanisms available to stakeholders, including hearings, petitions, and requests for supervisory review. Each of these mechanisms is described in this document. Of these, by far the most commonly used is a request for supervisory review under 21 CFR 10.75 (a “10.75 appeal”).
This section contains guidelines for filing a 10.75 appeal and provides a general description of the review process. Internal agency review is usually the quickest and most efficient means of formally resolving a dispute relating to a CDRH significant decision. Through this process, the supervisor of a Center employee will, at the request of an interested or aggrieved party, review a decision or action of the employee and issue a decision. The decision rendered by the supervisor, acting as the review authority, customarily takes one of the following forms: overturning the decision of the employee; upholding the employee decision; or, in some circumstances, referring the matter back to the employee for reconsideration under defined conditions. An opportunity may also arise for the review authority to mediate an agreement between the submitter and the employee while the review is in progress, which can be a means for expediting the resolution of the issues in dispute.
Section 517A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), added by section 603 of the FDA Safety and Innovation Act of 2012, includes new requirements pertaining to the process and timelines for 10.75 appeals of “significant decisions” regarding 510(k) premarket notifications, applications for premarket approval (PMAs), and applications for investigational device exemptions (IDEs) (in this guidance document, the term “significant decision” will refer to significant decisions pertaining to these submissions). FDA is proposing its interpretation of this provision, for example, what constitutes a “significant decision,” in a draft guidance document issued simultaneously with this final guidance document, entitled, “Center for Devices and Radiological Health Appeals Processes: Questions and Answers about 517A.”
2.1 General Considerations
2.1.1. Supervisory Review Hierarchy
A request for supervisory review should be directed to the next organizational level above the level at which the decision was made. Therefore, it is important to be aware of the signatory of the decision under dispute so that the request can be directed to the appropriate review authority. The organizational hierarchy varies across Offices, but in general the order is: Branch → Division → Office → Center → Commissioner. For example, a Not Substantially Equivalent (NSE) letter typically is signed by a Division Director, so a request for review of that decision would be directed to the Office Director. Note that the Office or Center Director may designate a Deputy Director to be their representative as the authority for a request made to that level. In this situation, a request for review heard by a Deputy is rendered on behalf of the Director and constitutes a review by that level of the organization.
Decisions rendered at the Center level may be further appealed to the Commissioner’s Office. A request for review by the Commissioner’s Office of a decision made at the Center level generally takes the form of a Petition or Appeal under 21 CFR Part 10 as described elsewhere in this document. As a matter of general practice, the Agency expects that available options for review up to the Center Director, such as under section 10.75, will have been exhausted before a Petition is filed with the Commissioner, although in certain cases time frames for preserving an appeal might mandate filing of an appeal to the Commissioner before exhaustion of Center-level review remedies.1 However, nothing in this guidance should be construed as constraining the ability of a stakeholder to exercise options for appeal or petition at any time that is permissible under applicable statutory and regulatory provisions.
2.1.2 Telescoped Review
In some situations, a supervisor considering a request for review may wish to engage in substantive discussions with individuals at a higher organizational level, such as his/her own supervisor, or others further up the supervisory chain. This may occur, for example, in matters pertaining to regulatory issues, new policy questions, or highly complex scientific questions. Engagement of a next-level supervisor in a matter under dispute does not necessarily disqualify the next-level supervisor from hearing the dispute on appeal; however, elevation of a dispute may be appropriate if the next-level supervisor has been significantly and substantively involved in the regulatory action under review. Certain circumstances may also warrant referral of the review directly to the next-level supervisor, up to and including the Center Director. In these situations, the Center intends that the review will be undertaken and decided by the next-level supervisor. For example, circumstances such as imminent risk to public health may warrant elevation of a Division-level appeal directly to the Center Director. A stakeholder wishing to elevate a dispute should indicate a request for telescoped review with an accompanying rationale. The decision to collapse two or more levels of review or to elevate a review is made solely at the Center’s discretion and the Center intends to document the rationale for the decision in the review decision letter.
2.1.3 New Information
A request for review under section 10.75 should be based on the information that was already present in the administrative file at the time of the decision that is being reviewed, as provided in 21 CFR 10.75(d). A submitter can add graphs, simple analyses, or other minor clarifications as part of the request and should clearly identify the information as new and minor, and the review authority may request such information from either the submitter or from CDRH employees involved in the decision that is being reviewed. If the request as submitted contains significant new information such as additional data that has not been previously reviewed, or substantially different analyses of existing data, then the matter will generally be referred back down to the original level for reconsideration; however, the review authority may, at his or her discretion, allow the introduction of new information in the interest of expediting a decision or reaching an agreement between the stakeholder and the Center.
2.1.4 Parallel Review
In some circumstances, a company with a request for review pending with the Center may wish to engage in a discussion with the review team with the goal of resolving the issues under dispute before the review process is completed. Alternatively, a company requesting review of a regulatory decision on a marketing application may submit a new application while the review of the previous decision is pending. These circumstances are sometimes called “parallel review.” The Center strongly discourages this approach, both because of the resources required to support the duplication of effort and because of the potential for confusion in reviewing a decision that is still under discussion and may be modified. Generally the Center will contact the company to ask which alternative it prefers. A company with a pending request for review should refrain from direct communication with the review team while the request is being considered; alternatively, if a company has filed a request for review and subsequently wishes to engage in a discussion with the review team in an effort to resolve the dispute, then the request should be withdrawn without prejudice.
In addition, because the filing of a request under section 10.75 does not stay other administrative or enforcement actions by the agency,2 the matter that is the subject of the request for supervisory review may also be under review in other administrative proceedings, such as a Part 16 hearing described in Section 5.5 of this document, or even a Civil Money Penalty proceeding. Similarly, an interested person may seek other forms of review during the pendency of a request under 10.75, such as reconsideration by the Commissioner under 21 CFR 10.33. However, the Center will generally decline to consider a section 10.75 request for supervisory review that involves a matter that is under active review by the Office of the Commissioner.
2.1.5 Bias and Retaliation
Handling an appeal or reconsideration of a matter in dispute is a routine part of the Center’s business processes. The Center is strongly committed to ensuring that interactions with entities doing business with the Center are free from bias or retaliation at every stage, including the filing of an appeal of a Center action. If the submitter of an appeal or request for review believes that Center staff is engaging in bias or retaliation consequent to the submitter filing an appeal or otherwise formally challenging an agency decision, those concerns can be brought to the attention of the Ombudsman. Evidence of bias or retaliation in the form of electronic mail messages, meeting or teleconference minutes, or the like, is very helpful in establishing a basis for requesting relief. Contact with the Ombudsman can be on a confidential basis if so requested, in which case the Center will protect the confidentiality of the information provided and the source of such information to the maximum extent possible under governing disclosure laws.
Note that an appeal or review meeting is not intended to be the forum for airing allegations of bias or misconduct. An allegation of bias, misconduct or other wrongdoing can be discussed with the Ombudsman and then submitted in writing directly to the Ombudsman, accompanied by documentation to support the allegation. The Ombudsman will investigate the allegations, make a finding as to whether bias and/or retaliation occurred, and determine what, if any, further actions should be taken. If after an initial investigation the Ombudsman decides that there is insufficient basis to sustain an allegation of bias or retaliation, the rationale for this determination will be discussed with the complainant, affording an opportunity for further discussion or presentation of additional evidence. If the Ombudsman decides that there is a legitimate basis to support an allegation of bias or retaliation, then the Ombudsman will pursue the matter through independent channels to the Commissioner’s Office. At that point a decision will be made whether to refer the matter for internal investigation.
In addition, a stakeholder who believes that they have been subjected to bias or misconduct on the part of CDRH employees may contact the FDA Office of Internal Affairs (OIA) and may also file a written complaint directly with the HHS Office of the Inspector General (OIG). Although the CDRH Ombudsman is available for consultation as desired, there is no requirement for prior interactions within CDRH before contacting OIA or OIG.
2.2 Process for Requesting Review
As provided in section 517A of the FD&C Act, a request for supervisory review (appeal) of a significant decision must be submitted not later than 30 days after such decision that is the subject of the appeal. There is no provision in the statute for extensions or waivers, or for partial submissions or “placeholders.” Appeals received by the Center later than 30 days after the date of a significant decision are not eligible for review under section 10.75. FDA recommends that a 10.75 appeal of any decision be submitted within 30 days of the decision, but we will generally permit greater flexibility with respect to the timeframe of appeals of actions that are not significant decisions. Generally, appeals of other decisions received after 60 days would be untimely.
The submitter of the request should submit hard copy and/or electronic documents via the processes established for premarket submissions and applications.
The request for supervisory review should be clearly marked “APPEAL” to ensure proper document processing and should identify any associated document number such as a 510(k) submission number. The submitter can provide a list of references to documents already in the administrative file or can include copies of these documents with the appeal package.
Each appeal submitted to CDRH is logged in by the Document Control Center. CDRH should respond to the appeal acknowledging receipt and assigning the appeal authority. If the appeal is not eligible for consideration, e.g., because it is untimely, then the response should explain the reason(s) why the appeal is ineligible and the matter should be considered closed.
2.3 Review Meeting or Teleconference
As described in section 517A of the FD&C Act, a person requesting supervisory review of a significant decision may request an in-person meeting or teleconference with the review authority. If this request is included in the request for supervisory review, the Center must schedule the meeting or teleconference to occur within 30 days of the request. For appeals of actions that are not significant decisions, it is up to the review authority whether to grant a meeting or teleconference to allow the submitter to present its case directly. FDA believes that most appeals of actions other than significant decisions can be decided without an in-person meeting or teleconference.
If a meeting or teleconference does take place, the Center intends the meeting to be an opportunity for direct interaction between the submitter and the review authority. One or more members of the review team and Branch Chief or other appropriate member of management should be present at the meeting at the invitation of the review authority. However, since the meeting is the submitter’s opportunity to make its case directly to the review authority, interactions between the review team and the submitter should be managed by the review authority to ensure that the submitter has an unfettered opportunity to state its case. Note that one possible outcome of a review meeting is for the review authority to negotiate a mediated agreement between the parties, should an appropriate opportunity arise.
To expedite resolution in cases where the submitter believes the circumstances of the decision subject to review can be presented effectively in writing, the submitter may elect to forego a meeting or teleconference. This is sometimes referred to as a “paper review” in that the dispute is considered on the merits of the administrative file plus the review package filed by the submitter.
In matters that are particularly complex or novel, the submitter may request that the review authority refer the dispute to external experts such as an Advisory Panel to make a recommendation to the review authority as provided in 21 CFR 10.75(b). The appeal authority may also elect to refer a matter to external expertise on its own initiative. A decision to convene an Advisory Panel to consider a section 10.75 request for review is at the discretion of the review authority. Note that this process differs from the procedure for requesting a meeting of the Medical Devices Dispute Resolution Panel for an appeal to the Center level, which is described in Section 3.3 of this document.
A more efficient means to obtain an external opinion on a matter in dispute may be to request that the review authority consider referring the matter to one or more external Subject Matter Experts (SMEs), such as Special Government Employees qualified to participate on Advisory Committees/Panels, to evaluate the matter in dispute and provide advice to the review authority. In this process, a document is drafted by the review authority that states the issue(s) in dispute and includes relevant documents for review. The review authority may provide to the submitter a copy of the document for comment and may also allow the submitter to suggest areas of expertise relevant to the issues in dispute, although the final version of the document and the specific individuals selected as SMEs are determined by the review authority. The document is assigned to the SMEs who, in turn, provide their assessment of the issues in writing to the review authority. The written responses of the SMEs become part of the administrative file for the review authority to consider when rendering a decision.
Because of the resources required to convene an Advisory Panel or secure the expertise of an external consultant, CDRH typically uses external experts only in unusual circumstances generally involving highly complex scientific and clinical matters.
The format for a request for review submitted under section 10.75 is not specified by regulation, and submitters may employ whatever format best meets their needs. This section describes a general-purpose format that has tended to be an effective means for conveying a review request. The descriptions in this section are guidelines intended to facilitate the Center’s timely processing of requests for review. Failure to follow these guidelines does not disqualify the request from review; however, it is incumbent on the submitter to ensure that the request includes sufficient information to permit a substantive review of the issues in dispute.
A common format for a review package consists of a four to six page executive summary in narrative form as a cover letter, together with copies of relevant documents cited in the executive summary as references or appendices. The executive summary can be organized in sections as follows:
- A statement that a review is being requested with (level of review, e.g., Director of the Office of Device Evaluation) in the matter of (510(k) or PMA number; post-approval study, etc.) under 21 CFR 10.75;
- A request for either an in-person meeting or a teleconference to provide the submitter an opportunity to make the case directly to the review authority, or a request for expedited review without a meeting or teleconference;
- If desired, a request for the review authority to convene a meeting of the relevant Advisory Panel, or a request for referral of the review to outside expertise in the form of a “homework assignment” along with a justification for either such request;
- A clear statement of the issue in dispute and a discussion of why the relief sought by the submitter should be granted.
The executive summary should conclude with an explicit statement of the relief or action being requested; e.g., overturn of a 510(k) NSE determination or a PMA Not-Approvable letter. If there is an acceptable alternative to a complete reversal of the decision being challenged, such as deletion of certain deficiencies and referral of the matter back to the review team for reconsideration under specific conditions, that alternative should be stated in the conclusion. As stated earlier, the review must be based only on the information already in the administrative file at the time of the decision that is the subject of the review.
2.6 Review Conclusion
The review process is concluded with the issuance of a decision letter. The letter describes the basis for the request for review, conveys the decision of the review authority, and explains the basis for the decision. Review decision letters commonly contain recommendations for further actions to resolve the matter(s) in dispute and typically describe options for further review or appeal, should the submitter be dissatisfied with the outcome. If the person requesting supervisory review of a significant decision is granted an in-person meeting or teleconference under section 517A of the FD&C Act, then a decision must be rendered within 30 days of the meeting or teleconference; otherwise, a decision must be rendered within 45 days of the request for supervisory review. However, if the matter has been referred to experts outside of the FDA as described in Section 2.4, section 517A of the FD&C Act does not specify a timeframe for rendering a decision.
3. The Medical Devices Dispute Resolution Panel
The Medical Devices Dispute Resolution Panel (DRP) is intended to provide a means for independent review of a scientific controversy or dispute between a stakeholder and FDA. The DRP operates under the provisions of FDA's Medical Devices Advisory Committee Charter and the processes that apply to Medical Devices Advisory Committees generally apply to the DRP except as described in this document. The DRP fulfills two statutory mandates under the FD&C Act: the requirement of section 515(g)(2)(B) for review of PMA approvals and denials by an advisory committee “which may not be panels under section 513;” and the requirement of section 562 for a process for review of scientific controversies by a sponsor, applicant, or manufacturer of a drug or device product for which no other section of the FD&C Act “provides a right of review of the matter in controversy...” Under section 562, CDRH may convene a meeting of the DRP to provide advice to the Center:
- As directed by the Center Director to provide advice on a scientific controversy or a matter in dispute that has come to the attention of the Center Director; or,
- Upon approval of a request by a stakeholder as part of an appeal to the Center level.
This section describes the processes that apply to requests for meetings of the DRP (apart from requests under section 515(g)(2), which are described in section 4.1 of this document) and general DRP considerations.
3.2 Panel Composition
Pursuant to the charter of the Medical Devices Advisory Committee, the DRP has five standing members, who are generally appointed for four-year terms, and three temporary members, as follows:
- Three standing voting members, including the Panel Chair, who are chosen for their general scientific expertise applicable to a wide range of issues;
- A non-voting member representing consumer interests;
- A non-voting member representing industry interests;
- A minimum of three temporary voting members who are chosen for their specific expertise and experience in the matter under consideration by the DRP.
Although each DRP meeting will include at a minimum the eight members described above, additional temporary voting or non-voting members may be included on each Panel roster to provide specific expertise as needed. Temporary panel members, including consultants, may be drawn from members of other Advisory Panels or may be Special Government Employees or other qualified consultants. Temporary panel members are typically selected specifically for expertise appropriate to each DRP panel meeting. Individuals who previously had substantial involvement in the matter under review, such as participation on a relevant Advisory Panel, are not eligible. Although interested parties will be apprised of the selections prior to the panel meeting, the individuals are chosen by FDA to ensure freedom from bias or conflicts and to ensure that appropriate expertise is represented on the panel. Concerns regarding the individuals selected as temporary voting members can be expressed in writing to the Ombudsman, who will investigate these concerns and note them in the administrative record of the DRP proceedings.
3.3 Filing a Request to Convene the DRP
An interested party who wishes to submit a request for review to the Center level may request that the DRP be convened to consider the dispute and make a recommendation to the Center Director. As with a request for a review authority to convene an Advisory Panel, a request to convene the DRP should be made within the context of a request for review at the Center level under section 10.75.3 A review request that includes a request to convene the DRP should generally be submitted within 30 days of the date of the action that is the subject of the dispute, although an extension for a defined time period may be requested from, and granted by, the Ombudsman. The format of this request can follow the guidelines described in this document in Section 2.5 and should include an explanation of the basis for the request. The Deputy Center Director, in consultation with the Ombudsman, will decide whether to grant the request and will convey the decision to the submitter, normally within 15 days of receipt of the request. If the request is denied, then the section 10.75 review process will go forward as described in Section 2 but without the involvement of the DRP.
3.4 Eligibility Review
A request to convene the DRP should meet the following criteria:
- The submitter should have exhausted other review options through the supervisory chain below the Center level; for instance, a section 10.75 request for review to the relevant Office Director;
- If the DRP is included in a section 10.75 request for review made to the Center, the matter under dispute should already have been the subject of an Advisory Panel meeting, although the Center Director may exercise discretion in this regard;
- The issue should primarily concern a scientific controversy4 and should not involve:
- a regulatory, legal, or statutory authority dispute;
- actual or alleged criminal activity;
- regulatory jurisdiction, such as Designation of Lead Center for a combination product;
- a matter not within the purview of the Center, such as designation of lead center for a combination product or a dispute already referred to the Commissioner’s Office; or
- allegations of bias or retaliation by FDA employees.
Special circumstances may warrant a section 10.75 review directly to the Center level, including a request to convene the DRP, before the review options at the Division and Office levels have been exhausted. These situations may include, for example, an issue that is of significant interest or impact to the public health, such as an innovative device intended to treat critically ill members of a vulnerable patient population for whom no other viable treatment alternative exists. If a stakeholder believes that such special circumstances exist, the matter should be discussed expeditiously with the Ombudsman.
3.5 Dispute Resolution Panel Process
As mentioned earlier, except where a different process is described in this section, the procedures for the DRP generally conforms to the process for FDA’s Medical Devices Advisory Committee. Once a decision has been made to convene the DRP, the process generally utilized for medical device advisory panel meetings is initiated. However, the sequence of events may be modified on an ad hoc basis as circumstances warrant for a specific Panel meeting.
In general the processes governing the DRP are similar to other medical devices advisory panels as described in the Medical Devices Advisory Committee Charter, with some important differences. First, an advisory panel is a process used to gather information to inform Center decision-making; a proceeding before the DRP, on the other hand, is an adversarial process in which the Center defends a decision that has already been made. In addition, while an advisory panel is convened at the behest of the agency and is run by the Center, with the applicant as a participant, the DRP provides a forum in which the Center and the applicant are both parties to the issues in dispute.
During the course of the DRP meeting, members of the panel may question the parties directly; however, no questioning by or debate between the parties should be permitted. Once deliberations have been completed, the Chair will determine whether consensus exists among the panel members and, if not, will call for a vote. The Chair will not vote except to cast a tie-breaking vote.
Within 15 days of the panel meeting, the Panel Chair will prepare a document providing a Statement of Findings and a Recommendation on the disposition of the issues under consideration, including any minority views. These documents will be issued to the Center Director or FDA Commissioner, as applicable, who will make the final decision.
Petitions may be filed to request that the Agency take or refrain from taking an action, to reconsider a decision, or to place in abeyance an action pending further consideration. This section is provided for information purposes only and should not be taken as conveying legal advice regarding options available to stakeholders.
The most common petitions are the Citizen Petition and the Request for Administrative Reconsideration.
4.1 Petitions under Section 515 of the FD&C Act
As provided in section 515(d)(4) of the FD&C Act, an application whose Premarket Approval Application (PMA) has been denied may file a petition to request that the Commissioner review the denial. Also under this section, any interested person may request review of a PMA Approval Order. Petitions under section 515(d)(4) are reviewed as described in section 515(g) of the FD&C Act and are typically filed as Petitions for Administrative Reconsideration under 21 CFR 10.33, which is described further in this document in Section 4.3. Section 515(g)(2)(B), which provides for referral of petitions under this section to an advisory committee, has been implemented by CDRH with the establishment of the Medical Devices Dispute Resolution Panel (DRP) as described in Section 3.1. Section 515(d)(4) requires that such petitions be filed within 30 days of the date of receipt of the denial of a PMA and does not provide for extension of this time frame.
Although the statute refers specifically to the denial of a PMA application, FDA’s regulations permit a sponsor to treat an approvable or a not approvable decision as a denial and request a 515(g)(2) hearing. See 21 CFR 814.44(e)(2)(ii), (f)(2). If a sponsor appeals an approvable or not approvable decision under 21 CFR 10.75 within CDRH5 and receives an appeal decision upholding the approvable or not approvable decision, FDA would consider the 10.75 appeal decision to be a new approvable or not approvable decision under 21 CFR 814.44(e) or (f).6 Therefore, the applicant may elect to treat this decision as a denial of approval of the PMA under 21 CFR 814.44(e)(2)(ii) or (f)(2), and may file a petition for review under 515(d)(4) within 30 days of such appeal decision. In this circumstance, the Center will treat the decision as a denial and will issue an order accordingly. See21 CFR 814.45(e)(3). To promote an orderly process and coherent administrative record, CDRH discourages contemporaneous appeal processes and generally will not consider a request for review under 21 CFR 10.75 after the filing of a petition for review under 515(d)(4).
The processes described in section 515(g)(2) are generally lengthy and resource-intensive for both petitioners and FDA, and, as suggested by use of the dispute resolution panel to fulfill the statutory requirement, can be adversarial. Alternative processes have historically provided a more streamlined pathway for elevating disputes about PMAs. For these reasons, the procedures provides by section 515(g)(2) have rarely been invoked.
4.2 Citizen Petition (21 CFR 10.30)
A citizen petition can be submitted by any person to challenge an FDA action or decision, or to request an action from FDA. Citizen petitions must conform to a specific format and must provide certain information. These requirements are explained in detail at 21 CFR Part 10, subpart B, and these regulations should be carefully reviewed before preparing and submitting a citizen petition. Among the informational items that must generally be included are:
- A citation of the statutory provisions upon which the petition is based (if known);
- A complete description of the action requested, including the exact wording of any proposed regulation or order;
- A statement of the factual and legal grounds for taking the requested action;
- Information on any environmental impact; and
- Certification that the petition includes the full information and views relied upon.
FDA may also request information on the economic impact of the requested action if it appears it would result in a significant economic impact.
A citizen petition must be filed with FDA’s Division of Dockets Management, the mailing address for which can be found on the FDA Web.
4.3 Petition for Administrative Reconsideration of Action (21 CFR 10.33)
A petition for administrative reconsideration can be filed by any person with regard to part or all of a decision of the Commissioner. In accordance with 21 CFR 10.33, the petition must be filed within 30 days of the decision involved. A petition submitted later will ordinarily be denied as untimely, although the FDA Commissioner has discretion to permit a petition to be filed after 30 days when there is good cause to do so.
A petition for administrative reconsideration must conform to a specific format and must provide certain information. These requirements are explained in detail at 21 CFR 10.33 and 10.20 and these regulations should be carefully reviewed before preparing and submitting a petition.
The petition must include:
- A statement of the decision to be reconsidered;
- The action FDA should take if the petition is granted; and
- The legal and factual grounds relied upon, including identification of relevant information and views that the petitioner contends were not previously or adequately considered when the decision was made.
No new information or views can be submitted in a petition for administrative reconsideration. The petition must be based exclusively on information in the administrative record on which the decision was made.
A petition for administrative reconsideration may be granted and the decision reconsidered if the FDA determines doing so is in the public interest and in the interest of justice. A petition for administrative reconsideration will be granted if FDA finds all of the following criteria have been met:
- The petition demonstrates that relevant information or views in the administrative record were not previously or not adequately considered;
- The position of the petitioner is not frivolous and is sought in good faith;
- The petition demonstrates sound public policy grounds for reconsideration; and
- Reconsideration is not outweighed by public health or other public interests.
Note that the granting of a petition for reconsideration means only that reconsideration will occur, not that the Commissioner has decided in favor of the petitioner. A petition for administrative reconsideration must be filed with FDA’s Division of Dockets Management, the mailing address for which can be found on the FDA Web site.
4.4 Petition for Administrative Stay of Action (21 CFR 10.35)
Under section 10.35, the Commissioner may elect to place in abeyance or extend the effective date of any action pending or following a decision on any matter. The stay may be requested to be indefinite or for a defined time period. A request for a stay must be filed within 30 days of the action for which the stay is requested, although the Commissioner may allow a petition after 30 days for good cause. A request under this section should clearly state the action for which the stay is requested as well as the grounds for requesting the stay. Note that, as is true of all administrative procedures under 21 CFR Part 10, the submission of a petition under section 10.35 does not, in itself, effect a stay of any administrative action, including enforcement action. A request for a stay of action should be filed with the Division of Dockets Management as described above. The Commissioner’s decision on the petition will be published in the Federal Register if the original action was so published.
4.5 Request for Reconsideration of Adverse Decisions on Mammography Facility Accreditation/Certification (21 CFR Part 900, Subpart B)
Under the Mammography Quality Standards Act (MQSA) (42 U.S.C. § 263b), all U.S. medical facilities offering mammography services must meet certain national quality standards and be certified by FDA following accreditation by an accreditation body (AB), which in turn has been approved by FDA. Any facility that has been denied accreditation is entitled to appeal the decision directly to the AB that rendered the decision. If the appellant facility cannot achieve satisfactory resolution of an adverse accreditation decision that precludes certification or recertification through a direct appeal to the AB, it may request reconsideration of the adverse decision by the Division of Mammography Quality Standards at the address shown below. Any such request for reconsideration must be submitted within 60 days of an adverse appeals decision by the AB. (See 21 CFR 900.15(d)(3)). Also, during the appeals process and reconsideration period, the appellant facility is not permitted to provide mammography services.
Three copies of a request for reconsideration should be directed to:
U.S. Food and Drug Administration
Center for Devices and Radiological Health
Division of Mammography Quality Standards
Attention: Program Management Branch
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Included with a reconsideration request must be the AB’s original denial of accreditation (including clinical or phantom image score sheets, when applicable), all information submitted by the facility to the AB relevant to the appeal (including all original films submitted to the AB), a copy of the AB’s adverse appeals decision (including clinical or phantom image score sheets, when applicable), and a statement of the bases for the facility’s disagreement with the AB’s decision.
Within 60 days after receipt of a reconsideration request, the Division of Mammography Quality Standards intends to issue a decision and notify the facility in writing of the decision and the facility’s options as a consequence of the decision. A facility that is dissatisfied with the Division’s decision following reconsideration is entitled to a formal hearing before the Departmental Appeals Board, Department of Health and Human Services.
Procedures are described in 21 CFR 900.15(d). Copies of regulations are available from the U.S. Government Printing Office. They may also be found and downloaded by accessing the CFR on the Internet and searching CFR titles and volumes.
A facility that wishes to challenge an order suspending or revoking an FDA certificate that was issued under authority of the MQSA may do so in a Part 16 hearing, in accordance with 21 CFR 900.14. This process is described further in Section 5.5.
Following is a discussion of the types of hearings that parties outside of FDA may request under Agency regulations. This discussion is not intended to be all-inclusive and should not be construed as recommending for or against any option available to a stakeholder. The availability of a hearing in any instance depends upon the specific circumstances of the case. A person interested in filing a request for a hearing should be aware that hearings may involve more procedural steps and take more time than other processes such as petitions and section 10.75 reviews as described previously. A request for a hearing should be filed with FDA’s Division of Dockets Management, the mailing address for which can be found on the FDA Web.
5.1 Formal Evidentiary Public Hearing (21 CFR Part 12)
A formal evidentiary hearing under 21 CFR Part 12 is available under the following circumstances:
- A person may request a formal evidentiary public hearing under the laws specified in 21 CFR 10.50, including section 515(g) of the FD&C Act on premarket approval applications (PMAs) and product development protocols (PDPs); or
- The Commissioner concludes that it is in the public interest to hold a formal evidentiary hearing on any matter before FDA.
A Part 12 hearing involving the issuance, amendment, or revocation of a regulation is initiated by the Commissioner, through a petition in the form specified in Part 12 or as described for a Citizen’s Petition under 21 CFR 10.30(h).
Hearing requests concerning the issuance, amendment, or revocation of a regulation must be submitted on or before the 30th day after the date of publication of a final regulation or the 30th day after publication of a notice withdrawing a proposal initiated by a petition under 21 CFR 10.25(a). If the hearing request involves the issuance, amendment, or revocation of an order (e.g., an order under section 515(g) of the FD&C Act), the request must be submitted within 30 days after the issuance of a notice of opportunity for hearing. (See 21 CFR 10.33(b)).
The Commissioner will review all filed requests for hearings as soon as possible and determine whether a hearing has been justified and whether other actions are appropriate.
A person with a right to a Part 12 hearing may waive that right and instead request a public hearing under Part 13, Part 14, or Part 15, all of which are described below. Part 12 discusses in detail the applicable procedures when a Part 12 hearing commences, including procedures for the submission of pleadings, prehearing conferences, presentation of evidence, and filing of motions. In general, two copies of any submissions, such as pleadings, are to be filed with the Division of Dockets Management per 21 CFR 12.80 and, in general, should conform to the requirements of 21 CFR 10.20.
5.2 Public Hearing Before A Board of Inquiry (21 CFR Part 13)
A hearing under Part 13 is held at the discretion of the FDA Commissioner, when specifically authorized by regulation, or as an alternative to a formal evidentiary public hearing. Generally, the purpose of such a hearing is to review medical, scientific and technical issues; the proceedings are conducted as a scientific inquiry and not a legal trial. The proceedings are informal and the rules of evidence do not apply. A notice of hearing will be published in the Federal Register, and submissions to the Board of Inquiry are to be filed with the Division of Dockets Management, as described previously, and generally served on each participant in the proceeding.
5.3 Public Hearing Before A Public Advisory Committee (21 CFR Part 14)
A hearing under Part 14 is held at the discretion of the FDA Commissioner, or when provided by law or regulations, or as an alternative to a formal evidentiary hearing. Hearings are available under this Part for, among other things, matters relating to the:
- review of a performance standard for a radiation-emitting electronic product by FDA’s Technical Electronic Product Radiation Safety Standards Committee (TEPRSSC);
- classification of devices under Part 860;
- establishment, amendment or revocation of a performance standard;
- review of a PMA or PDP;
- review of the Quality System (formerly Good Manufacturing Practice) regulation;
- establishment of minimum national uniform quality standards for mammography facilities.
Note that all meetings of the Medical Device Advisory Committee panels are held under Part 14. FDA will publish a notice in the Federal Register of advisory committee meetings. In general, ten copies of written submissions to a committee are to be sent to the executive secretary unless otherwise specified in the Federal Register notice. (See 21 CFR 14.35(a)). Submissions for a Public Hearing under Part 14 do not need to be sent to the Division of Dockets Management.
5.4 Public Hearing Before the FDA Commissioner (21 CFR Part 15)
A hearing under Part 15 is held at the discretion of the Commissioner, when provided by law or regulation, or as an alternative to a formal evidentiary hearing (where granted in the discretion of the Commissioner), to permit persons to present information and views at a public hearing on any matter pending before the FDA. Examples of issues that can be referred to a Part 15 hearing include, but are not limited to, the following:
- Proposals to allow persons to order custom devices;
- Proposed Quality System (formerly Good Manufacturing Practice) Regulation;
- Proposed exemptions from federal preemption of state and local device requirements (21 CFR 808.25(e)).
FDA will publish a notice of hearing in the Federal Register. The scope of a hearing is determined by the notice of hearing and any regulation under which the hearing is held. A person may submit information or views on the subject of the hearing in writing to the Division of Dockets Management as described previously. (See 21 CFR 15.25).
5.5 Regulatory Hearing Before the Food and Drug Administration (21 CFR Part 16)
A hearing under Part 16 is called at the discretion of the FDA Commissioner when considering regulatory action, or when provided by law or regulation. Part 16 provides an opportunity for a regulatory hearing on various matters, including but not limited to:
- Sections 520(g)(4) and (g)(5) of the FD&C Act, relating to disapproval of an Investigational Device Exemption, or notice of a proposed withdrawal of approval;
- 21 CFR 814.46(c), relating to withdrawal of approval of a PMA;
- Rescission of a 510(k) clearance;
- An order suspending or revoking an FDA certificate issued to a U.S. mammography facility pursuant to the MQSA.
A regulatory hearing is initiated by a notice of opportunity for hearing from FDA. A person offered a hearing has the amount of time specified in the notice to request a hearing. Under 21 CFR 16.26(a), a request for a hearing may be denied if the request fails to demonstrate a genuine and substantial issue of fact that warrants a hearing; therefore, the request should specify the grounds for the hearing request. FDA and the party requesting the hearing will, if feasible, at least one day before the hearing provide to each other written notice of any published articles or written information to be presented or relied on at the hearing. A regulatory hearing is informal and the rules of evidence do not apply. (See 21 CFR 16.60(c)).
6. Judicial Review
FDA is frequently asked about judicial remedies. A party seeking judicial review of a final action taken by FDA should consult its attorney or perform its own research of applicable statutes and regulations. It is not appropriate for FDA to offer advice or assistance concerning whether, and how, a party may seek judicial review of an adverse decision, and nothing in this guidance should be construed as constraining the ability of a stakeholder to exercise any remedies provided by statute or regulation.
In general, FDA believes it is in the public interest for parties to avail themselves of administrative remedies within the agency prior to engaging in litigation, so that FDA has the opportunity to reconsider and review any dispute concerning an FDA action before it is referred to judicial review. (See 21 CFR 10.45). In the event that a petitioner brings judicial action relating to a matter that is subject to a pending review under 21 CFR 10.75 or 10.33, or any other administrative process, the Commissioner may request that the court refer the matter back to the Agency or hold its review in abeyance pending completion of administrative reconsideration. (See 21 CFR 10.33(h)). Moreover, the Commissioner will generally consider a petition for reconsideration only before the petitioner brings legal action in the courts.
7. Paperwork Reduction Act of 1995
This guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).
The time required to complete this information collection is estimated to average 8 hours per response, including the time to review instructions, search existing data sources, gather the data needed, and complete and review the information collection. Send comments regarding this burden estimate to:
FDA PRA Staff,
Office of Operations,
Food and Drug Administration,
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0910-0738 (expires 08/31/2019).
1 For example, a sponsor of a PMA that has been disapproved may file a petition for review of such denial on or before the thirtieth day after receipt of the notice of denial. See section 515(d)(4) of the FD&C Act.
2 See 21 CFR 10.35 for requests for stays.
3 A request to convene a meeting of the DRP may also be part of a petition under 21 CFR 10.33, described in Section 4.3.
4 The Center intends to interpret this concept broadly so as to allow the DRP to consider a range of issues that may be associated with a scientific dispute. For example, a scientific dispute regarding clinical evidence may also involve questions regarding the need for a training program, which could be considered by the DRP within this broader context.
5 As discussed above, FDA's proposed interpretation of "significant decisions" subject to the new 30-day appeal deadline as a result of section 603 of FDASIA is discussed in the draft guidance document issued simultaneously with this final guidance document, entitled, "Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers about 517A."
6 FDA would not consider an applicant who submits a timely 10.75 appeal of an approvable or not approvable decision to have voluntarily withdrawn its PMA under 21 CFR 814.44(g).